Literature DB >> 15266206

Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study.

L Adrienne Cupples1, Lindsay A Farrer, A Dessa Sadovnick, Norman Relkin, Peter Whitehouse, Robert C Green.   

Abstract

PURPOSE: The REVEAL study is a randomized, controlled study of the psychological and behavioral impact of APOE disclosure in a risk assessment protocol provided to first degree relatives of patients with Alzheimer's disease. The protocol presents risk information as cumulative incidence curves. This article describes how these curves were estimated.
METHODS: Curves were calculated using Bayes' rule to compute the posterior survival curves incorporating APOE information.
RESULTS: A combination of survival data from the MIRAGE study and gender- and age-specific APOE odds ratios were used to create risk curves for males and females within each of the 6 APOE genotypes.
CONCLUSION: Utilizing comparative genotype relative risk information and survival data from family studies, estimates of gender-, age-, and genotype-specific risk can be generated for use in a risk assessment research study that features genotype disclosure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266206     DOI: 10.1097/01.gim.0000132679.92238.58

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  82 in total

1.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

Review 3.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

Review 4.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

5.  Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults.

Authors:  O C Okonkwo; G Xu; N M Dowling; B B Bendlin; A Larue; B P Hermann; R Koscik; E Jonaitis; H A Rowley; C M Carlsson; S Asthana; M A Sager; S C Johnson
Journal:  Neurology       Date:  2012-05-16       Impact factor: 9.910

Review 6.  Impact of genetic risk assessment on nutrition-related lifestyle behaviours.

Authors:  Jacqueline A Vernarelli
Journal:  Proc Nutr Soc       Date:  2012-10-25       Impact factor: 6.297

7.  A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Authors:  Robert C Green; Kurt D Christensen; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Charmaine D M Royal; Thomas O Obisesan; Robert Cook-Deegan; Erin Linnenbringer; Melissa Barber Butson; Grace-Ann Fasaye; Elana Levinson; J Scott Roberts
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

8.  Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.

Authors:  Cathleen D Zick; Charles J Mathews; J Scott Roberts; Robert Cook-Deegan; Robert J Pokorski; Robert C Green
Journal:  Health Aff (Millwood)       Date:  2005 Mar-Apr       Impact factor: 6.301

Review 9.  Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Authors:  J Scott Roberts; Wendy R Uhlmann
Journal:  Prog Neurobiol       Date:  2013-04-09       Impact factor: 11.685

10.  Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates.

Authors:  Thomas R Fanshawe; A Toby Prevost; J Scott Roberts; Robert C Green; David Armstrong; Theresa M Marteau
Journal:  Genet Test       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.